Do investigational MET inhibitors have potential for the treatment of gastric cancer?

被引：2
|
作者：
Athauda, Avani [1 ]
Chau, Ian [1 ]
机构：
[1] Royal Marsden Hosp NHS Fdn Trust, Gastrointestinal & Lymphoma Unit, Downs Rd, Sutton, Surrey, England
来源：
EXPERT OPINION ON INVESTIGATIONAL DRUGS | 2019年 / 28卷 / 04期
关键词：
MET; gastric cancer; biomarkers; receptor tyrosine kinase MET; GENE COPY NUMBER; DOUBLE-BLIND; AMPLIFICATION; ADENOCARCINOMA; RESISTANCE; EXPRESSION; SURVIVAL; THERAPY; CAPECITABINE; COMBINATION;
D O I：
10.1080/13543784.2019.1582641
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
[No abstract available]
引用
收藏
页码：299 / 302
页数：4
相关论文
共 50 条
  • [21] Novel investigational drugs for gastric cancer
    Vecchione, Loredana
    Orditura, Michele
    Ciardiello, Fortunato
    De Vita, Ferdinando
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2009, 18 (07) : 945 - 955
  • [22] Combined treatment with MET inhibitors and other therapies in lung cancer
    Bagai, Rakesh
    Ma, Patrick C.
    TRANSLATIONAL LUNG CANCER RESEARCH, 2012, 1 (03) : 214 - 218
  • [23] Emerging kinase inhibitors of the treatment of gastric cancer
    Vincenzi, Bruno
    Imperatori, Marco
    Silletta, Marianna
    Marrucci, Eleonora
    Santini, Daniele
    Tonini, Giuseppe
    EXPERT OPINION ON EMERGING DRUGS, 2015, 20 (03) : 479 - 493
  • [24] Investigational ErbB-2 tyrosine kinase inhibitors for the treatment of breast cancer
    Martinello, Rossella
    Milani, Andrea
    Geuna, Elena
    Zucchini, Giorgia
    Aversa, Caterina
    Nuzzo, Annamaria
    Montemurro, Filippo
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2016, 25 (04) : 393 - 403
  • [25] Adenosine pathway inhibitors: novel investigational agents for the treatment of metastatic breast cancer
    Rizzo, Alessandro
    Massafra, Raffaella
    Fanizzi, Annarita
    Rinaldi, Lucia
    Cusmai, Antonio
    Latorre, Agnese
    Zaccaria, Gian Maria
    Ronchi, Maria
    Telegrafo, Michele
    Gadaleta-Caldarola, Gennaro
    Giotta, Francesco
    Lorusso, Vito
    Palmiotti, Gennaro
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2022, 31 (07) : 707 - 713
  • [26] Investigational reverse transcriptase inhibitors for the treatment of HIV
    Cory, Theodore J.
    Midde, Narasimha M.
    Rao, P. S. S.
    Kumar, Santosh
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2015, 24 (09) : 1219 - 1228
  • [27] Do exercise oncology guidelines have to be met to obtain improvements in breast cancer outcomes?
    Sandler, Carolina X.
    Spence, Rosa
    Rye, Sheree
    Singh, Ben
    Tanner, Jodie
    Hayes, Sandi C.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2021, 17 : 192 - 192
  • [28] Do Exercise Oncology Guidelines Have To Be Met To Obtain Improvements In Breast Cancer Outcomes?
    Sandler, Carolina X.
    Spence, Rosa
    Rye, Sheree
    Singh, Ben
    Tanner, Jodie
    Hayes, Sandi
    MEDICINE & SCIENCE IN SPORTS & EXERCISE, 2020, 52 (07) : 483 - 483
  • [29] Electric fields have potential as a cancer treatment
    Miller, Johanna
    PHYSICS TODAY, 2007, 60 (08) : 19 - 20
  • [30] PD-1 Inhibitors: Do they have a Future in the Treatment of Glioblastoma?
    Khasraw, Mustafa
    Reardon, David A.
    Weller, Michael
    Sampson, John H.
    CLINICAL CANCER RESEARCH, 2020, 26 (20) : 5287 - 5296
12345